TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS
TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS
Tosoh Bioscience is introducing a new weak anion exchanger that offers a very high dynamic binding capacity while maintaining good peak resolution. Besides other applications this is of special interest for the purification of plasma proteins.
TOYOPEARL GigaCap DEAE-650 is the newest member of the renowned TOYOPEARL GigaCap series of high capacity ion exchange media. The polymeric base bead was chemically modified to provide a high number of anionic binding sites for increased resin capacity. The typical dynamic binding capacity (DBC) of over 150 g/L for bovine serum albumin exceeds the DBC of all other commercial available DEAE chromatography media. The resin was proved to be stable for more than 100 cleaning-in-place (CIP) cycles with 0.5 M NaOH. Good mass transfer kinetics enable the resin to maintain DBC at faster linear velocities and leads to a narrow elution peak. This results in smaller and more concentrated in-process pool volumes, thus reducing the amount of water and buffer needed. The high capacity and low back pressure creates opportunities for increased throughput in various anion exchange purification steps and is ideally suited for efficient plasma protein purification.
Contact:
TOSOH BIOSCIENCE GmbH
Zettachring 670567 Stuttgart, Germany
Tel. +49 (0)711 13257-0
Fax: +49 (0)711 13257-89
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
